MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Part of paid clinical trials in New York, New York.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00866177
Phase
PHASE2
Status
Completed

Conditions

  • Recurrent Melanoma
  • Stage III Skin Melanoma
  • Stage IV Skin Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Selumetinib — DRUG
    Given orally

Study Details

This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Mar 31, 2009
Status verified
Jun 2013
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013

Study Design

Enrollment
167 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Anti-tumor Response Defined as Either a CR, PR, or SD as Defined by RECIST [ Time Frame: Up to 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10065-

Find similar trials in New York, NY

By research site
Memorial Sloan-Kettering Cancer Center· New York, NY

Related Studies